Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

camoteskimab

A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin-18 (IL-18), with potential anti-inflammatory and antineoplastic activities. Upon administration, camoteskimab selectively targets and binds to IL-18, thereby inhibiting IL-18-mediated signaling and inflammation mediated by this pathway. In addition, this may inhibit IL-18-mediated immunosuppression in the multiple myeloma microenvironment. IL-18 is a member of the interleukin-1 (IL-1) cytokine superfamily. Elevated IL-18 level is associated with disease progression and poor prognosis in multiple myeloma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-IL-18 monoclonal antibody CERC-007
Code name:AEVI-007
CERC 007
CERC-007
CERC007
MEDI2338
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search